152 related articles for article (PubMed ID: 7715840)
1. The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective delta-opioid antagonist.
Ossipov MH; Kovelowski CJ; Porreca F
Neurosci Lett; 1995 Jan; 184(3):173-6. PubMed ID: 7715840
[TBL] [Abstract][Full Text] [Related]
2. Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat.
Ossipov MH; Kovelowski CJ; Vanderah T; Porreca F
Neurosci Lett; 1994 Nov; 181(1-2):9-12. PubMed ID: 7898778
[TBL] [Abstract][Full Text] [Related]
3. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin in the rat.
Drower EJ; Stapelfeld A; Rafferty MF; de Costa BR; Rice KC; Hammond DL
J Pharmacol Exp Ther; 1991 Nov; 259(2):725-31. PubMed ID: 1658309
[TBL] [Abstract][Full Text] [Related]
4. Effects of opioid receptor antagonists on the effects of i.v. morphine on carrageenin evoked c-Fos expression in the superficial dorsal horn of the rat spinal cord.
Catheline G; Le Guen S; Besson JM
Brain Res; 1999 Apr; 824(1):105-11. PubMed ID: 10095048
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole- and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception.
Vanderah TW; Lai J; Yamamura HI; Porreca F
Neuroreport; 1994 Dec; 5(18):2601-5. PubMed ID: 7696612
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
[TBL] [Abstract][Full Text] [Related]
7. Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
Beaudry H; Gendron L; Morón JA
Eur J Neurosci; 2015 Apr; 41(7):901--7. PubMed ID: 25639561
[TBL] [Abstract][Full Text] [Related]
8. Role of the kappa-opioid system in the attenuation of the morphine-induced place preference under chronic pain.
Suzuki T; Kishimoto Y; Misawa M; Nagase H; Takeda F
Life Sci; 1999; 64(1):PL1-7. PubMed ID: 10027746
[TBL] [Abstract][Full Text] [Related]
9. Effects of a highly selective nonpeptide delta opioid receptor agonist, TAN-67, on morphine-induced antinociception in mice.
Suzuki T; Tsuji M; Mori T; Misawa M; Endoh T; Nagase H
Life Sci; 1995; 57(2):155-68. PubMed ID: 7603296
[TBL] [Abstract][Full Text] [Related]
10. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.
Stanfa LC; Dickenson AH
Br J Pharmacol; 1993 Apr; 108(4):967-73. PubMed ID: 8485635
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of opioid dependence and interaction between opioid receptors.
Suzuki T; Kishimoto Y; Ozaki S; Narita M
Eur J Pain; 2001; 5 Suppl A():63-5. PubMed ID: 11798220
[TBL] [Abstract][Full Text] [Related]
13. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
Gouardères C; Jhamandas K; Sutak M; Zajac JM
Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
15. Morphine-induced in vivo release of spinal cholecystokinin is mediated by delta-opioid receptors--effect of peripheral axotomy.
Gustafsson H; Afrah AW; Stiller CO
J Neurochem; 2001 Jul; 78(1):55-63. PubMed ID: 11432973
[TBL] [Abstract][Full Text] [Related]
16. Involvement of spinal kappa opioid receptors in the antagonistic effect of dynorphins on morphine antinociception.
Song ZH; Takemori AE
Life Sci; 1991; 48(15):1447-53. PubMed ID: 1672725
[TBL] [Abstract][Full Text] [Related]
17. Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity.
Mellon RD; Bayer BM
Brain Res; 1998 Apr; 789(1):56-67. PubMed ID: 9602057
[TBL] [Abstract][Full Text] [Related]
18. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman JS; Mulvaney SA; Mosberg HI; Porreca F
Brain Res; 1987 Sep; 420(1):100-8. PubMed ID: 2823970
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.
Yadlapalli JSK; Ford BM; Ketkar A; Wan A; Penthala NR; Eoff RL; Prather PL; Dobretsov M; Crooks PA
Pharmacol Res; 2016 Nov; 113(Pt A):335-347. PubMed ID: 27637375
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular administration of morphine reduces mustard-oil-induced craniofacial-muscle pain behavior in lightly anesthetized rats.
Han SR; Lee MK; Lim KH; Yang GY; Jeon HJ; Ju JS; Yoon YW; Kim SK; Ahn DK
Eur J Pain; 2008 Apr; 12(3):361-70. PubMed ID: 17768078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
